retatrutide triple agonist clinical trial #obesity #osteoarthritis #clinicaltrials #medicine #research Triple hormone receptor agonist retatrutide

For those using compounded tirzepatide , reconstitution with bacteriostatic water follows standard protocols

It's better heart protection, better metabolic control

6 The four core trials: TRIUMPH-1 (general obesity, 80 weeks): the largest trial in the programme, with nested OSA and OA protocols

Common: Nausea, vomiting, diarrhea, or constipation Reduced appetite (sometimes too much) Mild low blood sugar (especially with other diabetes medications) Injection site reactions Less common but serious: Pancreatitis Gallbladder issues Kidney complications from dehydration Thyroid tumors (observed in rodent studies and still under investigation in humans) This is a non-exhaustive list

Your Personalized Journey Starts Here We believe that sustainable weight loss should be achieved through science, empathy, and a transparent approach